Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference
Dr. Sheth reviewed the current treatment paradigm for diabetic retinopathy.
- Dr. Sheth reviewed the current treatment paradigm for diabetic retinopathy.
- The majority of patients who are diagnosed have non-proliferative diabetic retinopathy (NPDR), but there is a high likelihood of progression to proliferative diabetic retinopathy (PDR) over time.
- APX3330 showed favorable safety and tolerability in diabetic patients that continued dosing their medications through the study durations to manage their diabetic comorbidities.
- We look forward to advancing our oral APX3330 program.”